CD8A and non-small cell lung carcinoma: Besides, Mazzaschi G et al. prospectively analyzed the PD-1+CD8+ T levels of peripheral blood in NSCLC patients receiving ICI therapies as first or more line treatment, and discovered that high PD-1+CD8+ T had positive impact on response and survival times [28].